Concomitant administration of the α-glucosidase inhibitor voglibose (AO-128) does not alter the pharmacokinetics of glibenclamide

European Journal of Clinical Pharmacology

Volumn 53, Issue 2, 1997, Pages 149-152

  Kleist, P ^a   Ehrlich, A ^b   Suzuki, Y ^a   Timmer, W ^b,d   Wetzelsberger, N ^b   Lucker P W ^b   Fuder, H ^b,c,e  

^a Takeda Pharma GmbH   (Germany)

^b Prof Dr Lucker GmbH   (Germany)

^c Clinical Pharmacology ^*  (Germany)

^d ALTANA PHARMA AG   (Germany)

^e PAREXEL INTERNATIONAL   (United States)

Author keywords

Glibenclamide; Voglibose

Indexed keywords

ANTIDIABETIC AGENT; GLIBENCLAMIDE; PLACEBO; VOGLIBOSE;

ADULT; ARTICLE; BIOAVAILABILITY; BIOEQUIVALENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; ULTRAVIOLET SPECTROPHOTOMETRY;

ADULT; ALPHA-GLUCOSIDASES; AREA UNDER CURVE; BLOOD GLUCOSE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; ENZYME INHIBITORS; GLYBURIDE; HUMANS; HYPOGLYCEMIC AGENTS; INOSITOL; MALE;

EID: 0030726954     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050354     Document Type: Article

References (12)

1. Baba S (1994) Characteristics of the α-glucosidase inhibitors. In: Baba S (ed) Diabetes: focus on α-glucosidase inhibitors. International trends in drug treatment. Churchill Livingstone, Japan pp 20-34
2. Chiasson J-L, Josse RG, Hunt JA, Palmason C, Rodger NW, Ross SA, Ryan EA, Tan MH, Wolever IMS (1994) The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial. Ann Int Med 121: 928-935
3. Gerard J, Lefebvre PJ, Luyckx AS (1984) Glibenclamide pharmacokinetics in acarbose-treated type 2 diabetics. Eur J Clin Pharmacol 27: 233-236
4. Göke B, Fuder H, Wieckhorst G, Theiss U, Stridde E, Littke T, Kleist P, Arnold R, Lücker PW (1995) Voglibose (AO-128) is an efficient α-glucosidase inhibitor and mobilizes the endogenous GLP-1 reserve. Digestion 56: 493-501
5. Halter JB, Morrow LA (1990) Use of sulfonylurea drugs in elderly patients. Diabetes Care 13 [Suppl 2]: 86-92
6. Jackson JE, Bressler R (1988) Use of oral hypoglycemics with caution. Geriatrics 8: 77-83
7. Odaka H, Matsuo T (1992) Effect of a disaccharidase inhibitor. AO-128, on post-prandial hyperglycemia in rats. J Jpn Soc Nutr Food Sci 45: 27-31
8. Reaven GM, Lardinois CK, Greenfield MS, Schwartz HC, Vreman HJ (1990) Effect of acarbose on carbohydrate and lipid metabolism in NIDDM patients poorly controlled by sulfonylureas. Diabetes Care 13 [Suppl 3]: 32-36
9. Scheen AJ, Lefèhvre PJ (1995) Antihyperglycaemic agents. Drug interactions of clinical importance. Drug Safety 12: 32-45
10. Shima K, Tanaka A, Ikegami H, Tabata M, Sawazaki N, Kumahara Y (1983) Effect of dietary fibre, glucomannan, on absorption of sulfonylurea in man. Horm Metab Res 15: 1-3
11. United Kingdom Prospective Diabetes Study Group (1995) United Kingdom prospective diabetes study (UKPDS) 13: relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin-dependent diabetes followed for three years. BMJ 310: 83-88
12. Williams G (1994) Management of non-insulin-dependent diabetes mellitus. Lancet 343:95-100